Ariel Carmeli: Our First ASCO as a Reversing Early Recurrence Team
Ariel Carmeli, Co-founder of Reversing Early Recurrence, posted on LinkedIn:
“Excited to attend ASCO25 and for the chance to share more about our work at RER (Reversing Early Recurrence) to help bring novel cancer treatments sooner when patients could benefit most.
This will be our first ASCO as a RER team – a lean, committed group assembling a state-of-the-art cancer care ecosystem to intercept cancer recurrence at its earliest stage, based on ctDNA, and give patients a possible opportunity for a cure.
In an article published in Nature Reviews Cancer we outlined how this system could speed drug development for solid tumors — enabling faster, cheaper, and smaller clinical trials by engaging the more than 100,000 patients who have been treated for an early-stage cancer but are at risk that the cancer will recur.
My co-authors include industry luminaries: Aparna Parikh, MD and Arielle Medford, MD, Mass General Cancer Center; Levi Garraway, MD/PhD and Nikhil Wagle, MD, Genentech; Eric S. Lander, PhD and Alex Ritchie, Science for America.
Please reach out if you are attending ASCO25 this weekend and interested to explore the transformative possibilities of novel treatments in earlier settings! Would love to connect across the ecosystem, with oncologists, drug developers, diagnostics, and tech innovators.”
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023